Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer

Maurie Markman, MD


November 23, 2021

Lung cancer remains the leading cause of cancer-related death for both men and women worldwide, with an estimated 1.8 million deaths attributed to the disease each year. Non–small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancer cases. It is among some of the most genome-varied and -deranged of all cancers, which generates enormous challenges for both prevention and treatment strategies. Driver oncogenic mutations have been increasingly elucidated by the clinical use of multiplex next-generation sequencing. Genomic alterations — mainly amplification and mutations — in erythroblastic oncogene B (ERBB2), which is also known as human epidermal growth factor receptor 2 (HER2), have emerged as distinctive oncogenic drivers in NSCLC and are considered a novel therapeutic target for treating NSCLC.

What do you know about HER2 mutations in NSCLC? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.